Clinical Trials Logo

Clinical Trial Summary

I This clinical trial aims to VIVO AND IN VITRO COMPARATIVE STUDY ON EFFICACY OF ANSA (experimental drug) & CRAN MAX (control drug) SACHET IN UNCOMPLICATED UTI in females. The main question[s] it aims to answer are: • Hypothesis I ANSA is an effective therapy for uncomplicated UTI treatment and inhibits or kills E.coli and other organisms in vitro and in vivo Null Hypothesis ANSA is not an effective therapy for uncomplicated UTI treatment and couldn't inhibit or kill E.coli and other organisms in vitro and in vivo Hypothesis II Cran Max is an effective therapy for uncomplicated UTIs and inhibits or kills E.coli and other organisms in vitro and in vivo Null Hypothesis Cran Max is not an effective therapy for uncomplicated UTI treatment and couldn't inhibit or kill E.coli and other organisms in vitro and in vivo


Clinical Trial Description

In this study, the emphasis is to evaluate the in vivo & in vitro efficacy of Ansa sachet having three APIs (Vaccinium macrocarpon, Saraca indica, Cimicifuga racemosa) in comparison with Cran max sachet in female patients having uncomplicated UTI. It is a single-blinded, randomized controlled trial. UTI (urinary tract infection) is mainly caused by E.coli and other associated organisms about 80% in females of fertile age and it occurs with less percentage in males. Uncommon recurrent UTIs is more prevalent in females than males. Post-menopausal women have higher rates of UTIs because of pelvic prolapse, lack of estrogen, loss of lactobacilli in the vaginal flora, increased peri-urethral colonization by Escherichia coli (E. coli), and a higher incidence of medical illnesses such as diabetes mellitus (DM).The microorganism that causes UTIs is similar, in most cases, to the sporadic infection. Most uro-pathogens from the rectal flora ascend to the bladder after colonizing in the peri urethral area and urethra. Keeping in mind that Helix Pharma designed ANSA in such a combination that it not only helps in the prevention of UTIs but also decreased recurrent UTIs as other APIs in ANSA have the capacity to normalize hormonal levels in females which is the basic cause of peri-menopausal and menopausal woman. The objective is to do a comparison of whether the Ansa sachet (experimental drug) or cran max sachet (control group) is a clinically good choice. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05572268
Study type Interventional
Source Shifa Ul Mulk Memorial Hospital
Contact Halima Nazar, Ph.D
Phone 03322889976
Email halimanazar76@gmail.com
Status Recruiting
Phase Phase 3
Start date August 12, 2021
Completion date August 12, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT02209220 - Impact of Automatic Positive Airway Pressure on Treatment Compliance in OSA Patients Awaiting Bariatric Surgery N/A
Enrolling by invitation NCT06070415 - Adherence to Exercises for Low Back Pain. N/A
Completed NCT04393987 - Effect Of Treatment Compliance Training Given To Patients With Bipolar Disorder N/A
Completed NCT04809519 - Integrative Nursing Based Multimodal Interventions for Uncontrolled Hypertensives N/A
Not yet recruiting NCT05941923 - Respiratory Critical Care Nurse Training Program N/A
Completed NCT04853836 - Olfactory Disfunction and Co-ultraPEALut Phase 4
Completed NCT06325579 - Immersive Virtual Reality for Dysphagia N/A
Not yet recruiting NCT06421038 - Efficacy of Thyme Honey in The Management of Oral Aphthous Ulcers N/A
Completed NCT04370145 - Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy Phase 4
Active, not recruiting NCT04536844 - Telehealth Follow-up in Patients With Rheumatoid Arthritis N/A
Recruiting NCT05844579 - The ICU LIBERATION Study
Recruiting NCT05465408 - Culturally Aware AET Non-Initiation Intervention N/A
Active, not recruiting NCT05115994 - Antihypertensive and PAP Treatment in Obstructive Sleep Apnea Patients With Hypertension (AHPAP)
Not yet recruiting NCT04517032 - ColoRectal Cancer in India: catastrOphiC expenDIture and Referral Pathways infLuencE on Presentation and Treatment